2,758 reports of this reaction
3.5% of all FLUDARABINE PHOSPHATE reports
#4 most reported adverse reaction
CYTOKINE RELEASE SYNDROME is the #4 most commonly reported adverse reaction for FLUDARABINE PHOSPHATE, manufactured by Fresenius Kabi USA, LLC. There are 2,758 FDA adverse event reports linking FLUDARABINE PHOSPHATE to CYTOKINE RELEASE SYNDROME. This represents approximately 3.5% of all 79,367 adverse event reports for this drug.
Patients taking FLUDARABINE PHOSPHATE who experience cytokine release syndrome should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CYTOKINE RELEASE SYNDROME is moderately reported among FLUDARABINE PHOSPHATE users, representing a notable but not dominant share of adverse events.
In addition to cytokine release syndrome, the following adverse reactions have been reported for FLUDARABINE PHOSPHATE:
The following drugs have also been linked to cytokine release syndrome in FDA adverse event reports:
CYTOKINE RELEASE SYNDROME has been reported as an adverse event in 2,758 FDA reports for FLUDARABINE PHOSPHATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CYTOKINE RELEASE SYNDROME accounts for approximately 3.5% of all adverse event reports for FLUDARABINE PHOSPHATE, making it a notable side effect.
If you experience cytokine release syndrome while taking FLUDARABINE PHOSPHATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.